行情

CAPR

CAPR

Capricor
NASDAQ

实时行情|Nasdaq Last Sale

2.710
+0.090
+3.45%
盘后: 2.670 -0.04 -1.49% 19:58 09/13 EDT
开盘
2.590
昨收
2.620
最高
2.830
最低
2.560
成交量
5.52万
成交额
--
52周最高
12.00
52周最低
2.300
市值
1,012.48万
市盈率(TTM)
-0.7211
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CAPR 新闻

  • 绝不延迟脱欧 英首相自比"绿巨人":越疯狂,就越强大
  • 环球网.1小时前
  • 沙特石油设施遇袭产量减半 美随时准备动用石油储备
  • 新京报网.2小时前
  • 新华国际时评:央行“放水”恐难纾欧元区之困
  • 新华网.2小时前
  • 沙特官员:周一石油产量将恢复到正常水平
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CAPR 简况

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
展开

Webull提供Capricor Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。